Literature DB >> 29328911

Western Diet Triggers NLRP3-Dependent Innate Immune Reprogramming.

Anette Christ1, Patrick Günther2, Mario A R Lauterbach3, Peter Duewell4, Debjani Biswas5, Karin Pelka6, Claus J Scholz2, Marije Oosting7, Kristian Haendler2, Kevin Baßler2, Kathrin Klee2, Jonas Schulte-Schrepping2, Thomas Ulas2, Simone J C F M Moorlag7, Vinod Kumar8, Min Hi Park9, Leo A B Joosten7, Laszlo A Groh7, Niels P Riksen7, Terje Espevik10, Andreas Schlitzer2, Yang Li8, Michael L Fitzgerald11, Mihai G Netea12, Joachim L Schultze13, Eicke Latz14.   

Abstract

Long-term epigenetic reprogramming of innate immune cells in response to microbes, also termed "trained immunity," causes prolonged altered cellular functionality to protect from secondary infections. Here, we investigated whether sterile triggers of inflammation induce trained immunity and thereby influence innate immune responses. Western diet (WD) feeding of Ldlr-/- mice induced systemic inflammation, which was undetectable in serum soon after mice were shifted back to a chow diet (CD). In contrast, myeloid cell responses toward innate stimuli remained broadly augmented. WD-induced transcriptomic and epigenomic reprogramming of myeloid progenitor cells led to increased proliferation and enhanced innate immune responses. Quantitative trait locus (QTL) analysis in human monocytes trained with oxidized low-density lipoprotein (oxLDL) and stimulated with lipopolysaccharide (LPS) suggested inflammasome-mediated trained immunity. Consistently, Nlrp3-/-/Ldlr-/- mice lacked WD-induced systemic inflammation, myeloid progenitor proliferation, and reprogramming. Hence, NLRP3 mediates trained immunity following WD and could thereby mediate the potentially deleterious effects of trained immunity in inflammatory diseases.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ASC; NLRP3 inflammasome; Western diet feeding; atherosclerosis; epigenetic reprogramming; granulocyte macrophage progenitors; innate immune memory; non-communicable diseases; sterile inflammation; trained immunity

Mesh:

Substances:

Year:  2018        PMID: 29328911      PMCID: PMC6324559          DOI: 10.1016/j.cell.2017.12.013

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  40 in total

1.  Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata.

Authors:  Filip K Swirski; Peter Libby; Elena Aikawa; Pilar Alcaide; F William Luscinskas; Ralph Weissleder; Mikael J Pittet
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor α system and interleukin-10.

Authors:  Ingunn Narverud; Thor Ueland; Marit S Nenseter; Kjetil Retterstøl; Vibeke H Telle-Hansen; Bente Halvorsen; Leiv Ose; Pål Aukrust; Kirsten B Holven
Journal:  Atherosclerosis       Date:  2010-11-01       Impact factor: 5.162

3.  ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation.

Authors:  Laurent Yvan-Charvet; Tamara Pagler; Emmanuel L Gautier; Serine Avagyan; Read L Siry; Seongah Han; Carrie L Welch; Nan Wang; Gwendalyn J Randolph; Hans W Snoeck; Alan R Tall
Journal:  Science       Date:  2010-05-20       Impact factor: 47.728

4.  Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia.

Authors:  Mariame El Messal; Jean-Louis Beaudeux; Anas Drissi; Philippe Giral; Rachid Chater; Eric Bruckert; Ahmed Adlouni; M John Chapman
Journal:  Clin Chim Acta       Date:  2005-11-08       Impact factor: 3.786

5.  Interleukin-1 gene expression in rabbit vascular tissue in vivo.

Authors:  S K Clinton; J C Fleet; H Loppnow; R N Salomon; B D Clark; J G Cannon; A R Shaw; C A Dinarello; P Libby
Journal:  Am J Pathol       Date:  1991-04       Impact factor: 4.307

6.  Gout-associated uric acid crystals activate the NALP3 inflammasome.

Authors:  Fabio Martinon; Virginie Pétrilli; Annick Mayor; Aubry Tardivel; Jürg Tschopp
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

7.  NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.

Authors:  Peter Duewell; Hajime Kono; Katey J Rayner; Cherilyn M Sirois; Gregory Vladimer; Franz G Bauernfeind; George S Abela; Luigi Franchi; Gabriel Nuñez; Max Schnurr; Terje Espevik; Egil Lien; Katherine A Fitzgerald; Kenneth L Rock; Kathryn J Moore; Samuel D Wright; Veit Hornung; Eicke Latz
Journal:  Nature       Date:  2010-04-29       Impact factor: 49.962

8.  Atherogenic diets enhance endotoxin-stimulated interleukin-1 and tumor necrosis factor gene expression in rabbit aortae.

Authors:  J C Fleet; S K Clinton; R N Salomon; H Loppnow; P Libby
Journal:  J Nutr       Date:  1992-02       Impact factor: 4.798

9.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization.

Authors:  Veit Hornung; Franz Bauernfeind; Annett Halle; Eivind O Samstad; Hajime Kono; Kenneth L Rock; Katherine A Fitzgerald; Eicke Latz
Journal:  Nat Immunol       Date:  2008-07-11       Impact factor: 25.606

10.  Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail.

Authors:  Daniella Brasacchio; Jun Okabe; Christos Tikellis; Aneta Balcerczyk; Prince George; Emma K Baker; Anna C Calkin; Michael Brownlee; Mark E Cooper; Assam El-Osta
Journal:  Diabetes       Date:  2009-02-10       Impact factor: 9.461

View more
  279 in total

Review 1.  Therapeutic targeting of trained immunity.

Authors:  Willem J M Mulder; Jordi Ochando; Leo A B Joosten; Zahi A Fayad; Mihai G Netea
Journal:  Nat Rev Drug Discov       Date:  2019-07       Impact factor: 84.694

Review 2.  Modifiable Cardiovascular Risk, Hematopoiesis, and Innate Immunity.

Authors:  Maximilian J Schloss; Filip K Swirski; Matthias Nahrendorf
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

Review 3.  Immunometabolic Crosstalk: An Ancestral Principle of Trained Immunity?

Authors:  Sider Penkov; Ioannis Mitroulis; George Hajishengallis; Triantafyllos Chavakis
Journal:  Trends Immunol       Date:  2018-11-29       Impact factor: 16.687

Review 4.  Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.

Authors:  Niki Karachaliou; Manuel Fernandez-Bruno; Jillian Wilhelmina Paulina Bracht; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2018-12

Review 5.  Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology.

Authors:  Daniel F J Ketelhuth; Esther Lutgens; Magnus Bäck; Christoph J Binder; Jan Van den Bossche; Carolin Daniel; Ingrid E Dumitriu; Imo Hoefer; Peter Libby; Luke O'Neill; Christian Weber; Paul C Evans
Journal:  Cardiovasc Res       Date:  2019-07-01       Impact factor: 10.787

6.  Is Inflammasome a Potential Target of Prophylaxis in Rheumatic Heart Disease?

Authors:  Teneema Kuriakose; Thirumala-Devi Kanneganti
Journal:  Circulation       Date:  2018-12-04       Impact factor: 29.690

7.  Inflammation, Inflammasome Activation, and Atrial Fibrillation.

Authors:  David R Van Wagoner; Mina K Chung
Journal:  Circulation       Date:  2018-11-13       Impact factor: 29.690

Review 8.  Epithelial cells: liaisons of immunity.

Authors:  Samantha B Larsen; Christopher J Cowley; Elaine Fuchs
Journal:  Curr Opin Immunol       Date:  2019-12-23       Impact factor: 7.486

Review 9.  Role of innate immune cells in metabolism: from physiology to type 2 diabetes.

Authors:  Elise Dalmas
Journal:  Semin Immunopathol       Date:  2019-04-05       Impact factor: 9.623

Review 10.  Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators.

Authors:  Charles N Serhan; Bruce D Levy
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.